These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8105596)

  • 1. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential.
    Greenshaw AJ
    Trends Pharmacol Sci; 1993 Jul; 14(7):265-70. PubMed ID: 8105596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astra Award Lecture. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Dec; 71(6):401-15. PubMed ID: 1362267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.
    Greenshaw AJ; Silverstone PH
    Drugs; 1997 Jan; 53(1):20-39. PubMed ID: 9010647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
    Faerber L; Drechsler S; Ladenburger S; Gschaidmeier H; Fischer W
    Eur J Pharmacol; 2007 Mar; 560(1):1-8. PubMed ID: 17316606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolytic potential of 5-HT3 receptor antagonists.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Mar; 70(3):157-62. PubMed ID: 1349746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT3 receptors.
    Costall B; Naylor RJ
    Curr Drug Targets CNS Neurol Disord; 2004 Feb; 3(1):27-37. PubMed ID: 14965242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles].
    Miyata K; Honda K
    Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):143-52. PubMed ID: 7959407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances with 5-HT
    Juza R; Vlcek P; Mezeiova E; Musilek K; Soukup O; Korabecny J
    Med Res Rev; 2020 Sep; 40(5):1593-1678. PubMed ID: 32115745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin and psychiatric disorders. A key to new therapeutic approaches.
    Costall B; Naylor RJ
    Arzneimittelforschung; 1992 Feb; 42(2A):246-9. PubMed ID: 1586395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT3 receptor antagonists and migraine therapy.
    Ferrari MD
    J Neurol; 1991; 238 Suppl 1():S53-6. PubMed ID: 2045832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological properties and functions of central 5-HT3 receptors.
    Costall B; Naylor RJ
    Therapie; 1991; 46(6):437-44. PubMed ID: 1840228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The breadth of action of the 5-HT3 receptor antagonists.
    Costall B
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():3-9. PubMed ID: 8201244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for treatment of psychoactive substance use disorders with serotonergic medications.
    Sellers EM; Higgins GA; Tomkins DM; Romach MK; Toneatto T
    J Clin Psychiatry; 1991 Dec; 52 Suppl():49-54. PubMed ID: 1752860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
    Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
    Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice.
    Rodgers RJ; Cole JC; Tredwell JM
    Psychopharmacology (Berl); 1995 Feb; 117(3):306-12. PubMed ID: 7770606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic medications for children and adolescents.
    Gracious BL; Findling RL
    Pediatr Ann; 2001 Mar; 30(3):138-45. PubMed ID: 11257943
    [No Abstract]   [Full Text] [Related]  

  • 19. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
    Humphrey PP; Bountra C; Clayton N; Kozlowski K
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.
    Artaiz I; Romero G; Zazpe A; Monge A; Calderó JM; Roca J; Lasheras B; Del Río J
    Psychopharmacology (Berl); 1995 Jan; 117(2):137-48. PubMed ID: 7753959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.